Keros Therapeutics to Present at Upcoming Healthcare Conferences
07 Novembre 2023 - 2:00PM
Keros Therapeutics, Inc. (“Keros”) (Nasdaq: KROS), a clinical-stage
biopharmaceutical company focused on developing and commercializing
novel therapeutics to treat a wide range of patients with disorders
that are linked to dysfunctional signaling of the transforming
growth factor-beta (“TGF-ß”) family of proteins, today announced
that Keros’ President and Chief Executive Officer Jasbir S. Seehra,
Ph.D., will present at the following healthcare conferences:
Stifel 2023 Healthcare Conference
- Date and Time:
Tuesday, November 14, 2023 at 2:25 p.m. Eastern time
- Link: A live audio
webcast will be available at
https://wsw.com/webcast/stifel83/kros/2121198
- Format: Corporate
Presentation
Piper Sandler 35th Annual Healthcare
Conference
- Date and Time:
Wednesday, November 29, 2023 at 2:30 p.m. Eastern time
- Link: A live audio
webcast will be available at
https://event.webcasts.com/starthere.jsp?ei=1643084&tp_key=16bfdeff38
- Format: Fireside
Chat
For each presentation, an archived replay will be accessible in
the Investors section of the Keros website
at https://ir.kerostx.com for up to 90 days following the
conclusion of each event.
About Keros Therapeutics, Inc.
Keros is a clinical-stage biopharmaceutical company focused on
developing and commercializing novel therapeutics to treat a wide
range of patients with disorders that are linked to dysfunctional
signaling of the TGF-ß family of proteins. We are a leader in
understanding the role of the TGF-ß family of proteins, which are
master regulators of the growth, repair and maintenance of blood
cells and a number of tissues, including bone, skeletal muscle,
adipose and heart tissue. By leveraging this understanding, we have
discovered and are developing large and small molecules that have
the potential to provide meaningful and potentially
disease-modifying benefit to patients. Keros’ lead protein
therapeutic product candidate, KER-050 (elritercept), is being
developed for the treatment of low blood cell counts, or
cytopenias, including anemia and thrombocytopenia, in patients with
MDS and in patients with myelofibrosis. Keros’ second product
candidate, KER-012, is being developed for the treatment of
pulmonary arterial hypertension and for the treatment of
cardiovascular disorders. Keros’ third product candidate, KER-065,
is being developed for the treatment of neuromuscular diseases,
with an initial focus on Duchenne muscular dystrophy.
Investor Contact:Justin
Frantzjfrantz@kerostx.com 617-221-6042
Grafico Azioni Keros Therapeutics (NASDAQ:KROS)
Storico
Da Ago 2024 a Set 2024
Grafico Azioni Keros Therapeutics (NASDAQ:KROS)
Storico
Da Set 2023 a Set 2024